ClearBridge Investments - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 506 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
ClearBridge Investments ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$73,173,991
-16.1%
1,074,982
+0.6%
0.07%
-11.4%
Q2 2023$87,218,524
+34.3%
1,068,462
+22.0%
0.08%
+27.4%
Q1 2023$64,959,407
-18.8%
875,582
-9.3%
0.06%
-21.5%
Q4 2022$80,002,738
+32.1%
965,284
+352.5%
0.08%
+29.5%
Q3 2022$60,579,000
-17.8%
213,308
+0.3%
0.06%
-11.6%
Q2 2022$73,716,000
-17.7%
212,660
+2.8%
0.07%
+3.0%
Q1 2022$89,622,000
-16.7%
206,959
-0.5%
0.07%
-8.2%
Q4 2021$107,631,000
+6.5%
208,046
-0.3%
0.07%
+1.4%
Q3 2021$101,068,000
+6.9%
208,572
-0.7%
0.07%
+9.1%
Q2 2021$94,560,000
+17.4%
210,013
-0.4%
0.07%
+10.0%
Q1 2021$80,520,000
+20.5%
210,824
+0.2%
0.06%
+15.4%
Q4 2020$66,832,000
+25.7%
210,462
-2.0%
0.05%
+13.0%
Q3 2020$53,178,000
-5.7%
214,662
+0.5%
0.05%
-9.8%
Q2 2020$56,394,000
+142.3%
213,558
+74.0%
0.05%
+104.0%
Q1 2020$23,279,000122,7680.02%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2021
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders